{(1S,2R)-1-(3-allyloxy-benzyl)-3-[benzyloxycarbonyl-(3-isopropylbenzyl)-amino]-2-hydroxy-propyl}-carbamic acid tert-butyl ester | 900800-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {(1S,2R)-1-(3-allyloxy-benzyl)-3-[benzyloxycarbonyl-(3-isopropylbenzyl)-amino]-2-hydroxy-propyl}-carbamic acid tert-butyl ester
• 英文别名: benzyl N-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-(3-prop-2-enoxyphenyl)butyl]-N-[(3-propan-2-ylphenyl)methyl]carbamate
• CAS: 900800-10-4
• 化学式: C₃₆H₄₆N₂O₆
• 分子量: 602.771
• InChiKey: NYJLCANGULXOFC-JHOUSYSJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  44
• 可旋转键数：
  17
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  97.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  {(1S,2R)-1-(3-allyloxy-benzyl)-3-[benzyloxycarbonyl-(3-isopropylbenzyl)-amino]-2-hydroxy-propyl}-carbamic acid tert-butyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以100%的产率得到C₃₁H₃₈N₂O₄
  参考文献：
  名称：

  Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application

  摘要：

  A series of macrocyclic peptidic BACE-1 inhibitors was designed. While potency on BACE-1 was rather high, the first set of compounds showed poor brain permeation and high efflux in the MDRI-MDCK assay. The replacement of the secondary benzylamino group with a phenylcyclopropylamino group maintained potency on BACE-1, while P-glycoprotein-mediated efflux was significantly reduced and brain permeation improved. Several compounds from this series demonstrated acute reduction of Ab in human APP-wildtype transgenic (APP51/16) mice after oral administration. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.092
• 作为产物：
  描述：

  、 氯甲酸苄酯 在 sodium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 以100%的产率得到{(1S,2R)-1-(3-allyloxy-benzyl)-3-[benzyloxycarbonyl-(3-isopropylbenzyl)-amino]-2-hydroxy-propyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application

  摘要：

  A series of macrocyclic peptidic BACE-1 inhibitors was designed. While potency on BACE-1 was rather high, the first set of compounds showed poor brain permeation and high efflux in the MDRI-MDCK assay. The replacement of the secondary benzylamino group with a phenylcyclopropylamino group maintained potency on BACE-1, while P-glycoprotein-mediated efflux was significantly reduced and brain permeation improved. Several compounds from this series demonstrated acute reduction of Ab in human APP-wildtype transgenic (APP51/16) mice after oral administration. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.092

文献信息

• Macrocyclic Compounds Useful as Bace Inhibitors
  申请人：Betschart Claudia

  公开号：US20080132477A1

  公开（公告）日：2008-06-05

  The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

  本发明涉及具有公式(I)的新型大环化合物，其中所有变量如说明书中所定义，大环环中包含的环原子数为14、15、16或17，以自由碱形式或酸加成盐形式存在，以及它们的制备方法、作为药物的使用以及包含它们的药物。
• MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS
  申请人：Novartis AG

  公开号：EP1851208A1

  公开（公告）日：2007-11-07
• [EN] MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS<br/>[FR] COMPOSES MACROCYCLIQUES SERVANT D'INHIBITEURS DE BACE
  申请人：NOVARTIS AG

  公开号：WO2006074950A1

  公开（公告）日：2006-07-20

  [EN] The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
  [FR] L'invention concerne des composés macrocycliques de formule (I), dans laquelle toutes les variables sont telles que définies dans la spécification, le nombre d'atomes cycliques inclus dans l'anneau macrocyclique étant de 14, 15, 16 ou 17, sous forme de base libre ou de sel d'addition acide. La présente invention porte également sur leur préparation, sur leur utilisation en tant que médicaments et sur des médicaments les contenant.